From CNBC:

Shares of Moderna surged over 15% on Tuesday after Oppenheimer upgraded the stock, predicting the company could launch five products by 2026. The upgrade follows a difficult 2023 when its Covid vaccine demand dropped, causing a 45% stock decline. Oppenheimer expects a rebound in Covid vaccine sales starting in 2025 due to increased awareness and education about the disease.

The firm is particularly optimistic about Moderna’s potential pipeline, including possible product launches in the next year that could boost 2025 sales. This includes potential approvals for a vaccine targeting respiratory syncytial virus and an experimental flu vaccine. The company also plans to file for FDA approval of its personalized cancer vaccine in the next few years.

Moderna’s partner, Merck, is studying the cancer vaccine in combination with a therapy for the treatment of melanoma and other cancers. The company expects sales growth in 2025, highlighted by the potential approval of its combination shot targeting Covid and the flu, as early as 2025. It expects revenue to fall to $4 billion in 2024 before rebounding in 2025 and breaking even in 2026. It also plans to launch up to 15 products in the next five years.



Read more: Moderna stock jumps after Oppenheimer upgrade on pipeline potential